WT1 and chronic myelogenous leukemia, BCR-ABL1 positive: In NCT01621724, WT1-specific T cells persisted one year after infusion in four out of a total of seven patients with AML and chronic myeloid leukemia (CML) (outcomes of clinical trials using TCR-T cells for AML are listed in Table 4) [51].